Cytogenetics News and Research RSS Feed - Cytogenetics News and Research

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy. [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods. [More]
Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. [More]
NeoGenomics' revenue increases 27% to $23.0 million in first quarter 2015

NeoGenomics' revenue increases 27% to $23.0 million in first quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015. [More]
NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2014. [More]
OGT study explores successful adoption of CytoSure ISCA array at Sheffield Children's NHS Foundation Trust

OGT study explores successful adoption of CytoSure ISCA array at Sheffield Children's NHS Foundation Trust

Oxford Gene Technology, The Molecular Genetics Company, explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays. As the result of a highly stringent National Health Service tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on the quality of data and analysis software. [More]
Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems, Mayo Clinic partner to develop next generation of cytogenetics imaging software

Leica Biosystems and Mayo Clinic's Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software. The new tool will optimize software workflow and improve the overall user experience for cytogenetics imaging technicians. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Scientists identify new biomarker for diagnosing cause of thyroid cancer

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N. [More]
CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

CAP awards accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to The Children's Hospital of Philadelphia Pathology & Laboratory Medicine, Philadelphia, Pennsylvania based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. [More]
NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS). [More]
Greenwood Genetic and Clemson receive first round of fund from SRHC

Greenwood Genetic and Clemson receive first round of fund from SRHC

Seven research projects from Greenwood Genetic Center and Clemson University faculty were selected to receive the first round of funding provided by Self Regional Healthcare (SRHC). [More]
Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit. [More]
Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncol-gicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma. [More]
Researchers reproduce tumor chromosomal translocations in human cells

Researchers reproduce tumor chromosomal translocations in human cells

Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukaemia and Ewing's sarcoma. [More]
Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR). [More]
NeoGenomics selects Aurora as primary partner for molecular testing

NeoGenomics selects Aurora as primary partner for molecular testing

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States. [More]
Advertisement
Advertisement